dc.contributor.author |
Koca, S |
|
dc.contributor.author |
Besiroglu, M |
|
dc.contributor.author |
Ozcelik, M |
|
dc.contributor.author |
Karaca, M |
|
dc.contributor.author |
Bilici, M |
|
dc.contributor.author |
Hacioglu, B |
|
dc.contributor.author |
Dogu, GG |
|
dc.contributor.author |
Kaplan, NB |
|
dc.contributor.author |
Oruc, Z |
|
dc.contributor.author |
Aydin, D |
|
dc.contributor.author |
Dane, F |
|
dc.date.accessioned |
2022-10-11T13:13:22Z |
|
dc.date.available |
2022-10-11T13:13:22Z |
|
dc.date.issued |
2021 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/75637 |
|
dc.description.abstract |
Purpose |
|
dc.description.abstract |
Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. |
|
dc.description.abstract |
Materials and methods |
|
dc.description.abstract |
We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. |
|
dc.description.abstract |
Results |
|
dc.description.abstract |
The median age was 50 years (range, 38-58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade >= 3 toxicities were fatigue, anorexia, weight loss, and liver disorder. |
|
dc.description.abstract |
Conclusion |
|
dc.description.abstract |
Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas. |
|
dc.source |
JOURNAL OF ONCOLOGY PHARMACY PRACTICE |
|
dc.title |
Pazopanib for metastatic soft-tissue sarcoma: A multicenter |
|
dc.title |
retrospective study |
|